Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

(2009) D. Ross Camidge et al.   ANTI-CANCER DRUGS

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer

(2008) M. H. Cullen et al.   ANNALS OF ONCOLOGY

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs

(2008) T Gelardi et al.   BRITISH JOURNAL OF CANCER

Reduction of HLA-DR+ Lymphocytes after Treatment with Enzastaurin in Patients with Metastatic Thyroid Cancer

(2008) Manfred Smetak et al.   CHEMOTHERAPY

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL

(2008) Johannes Rieger et al.   JOURNAL OF NEUROCHEMISTRY